- Conditions
- Systemic Lupus Erythematosus
- Interventions
- SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 22
- States / cities
- Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more
Location Directory
Clinical trials in Phoenix, Arizona
This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8148
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 745–756 of 8,148 matching trials in Phoenix, AZ.
Live ClinicalTrials.gov results.
Institutions in Phoenix
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 432
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
- Conditions
- Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Interventions
- ONC-392, Pembrolizumab
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 21
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
- Interventions
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
- Conditions
- Alzheimer Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more
- Conditions
- Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
- Interventions
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
- Radiation · Other · Biological + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad pegol (ACP)
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Placebo, Camlipixant
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 112
- States / cities
- Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 91 more
- Conditions
- Obesity, Overweight, Overnutrition
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
- Interventions
- ALK-001, Placebo
- Drug
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more
- Conditions
- Myositis
- Interventions
- Nipocalimab, Placebo, Glucocorticoids
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more